Drug Overview
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
Table of Contents
Product ProfilesXolair: Asthma
List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: Drug assessment summary of Xolair in asthma
Figure 2: Assessment summary of key marketed and pipeline drugs for asthma
Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
4 Table 1: Xolair drug profile
Table 2: Xolair pivotal trial data in asthma
Table 3: Xolair late-phase trial data in asthma
Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
